Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction

Not Applicable

• Conditions: Meibomian Gland Dysfunction; Dry Eye Syndromes; Dry Eye

• Registration Number: NCT04425551
• Lead Sponsor: Naval Hospital, Athens

Brief Summary

The modern treatment of meibomian gland dysfunction(MGD) is based on anti-inflammatory drops or oral antibiotics for decreasing dry eye disease (DED) associated inflammation, warm compresses for liquefying the thicker meibum, and lid hygiene for reducing the bacterial overload. But, such treatments have shown limited effectiveness to a large proportion of patients with MGD, due to the multifactorial background of the disease. Thus, alternative approaches aiming at different aspects of the DED pathophysiology are needed.

Elimination of posterior lid-margin hyperemia with telangiectasia could be a treatment target for reducing the secretion of inflammatory mediators in the course of MGD. Using the mechanism of photocoagulation via selective thermolysis, laser light could contribute to the destruction of abnormal vessels at the posterior lid-margin and thus, the reduction of inflammation. Recently, sub-threshold (micropulse) laser photocoagulation was introduced in ophthalmology and offers significant clinical advantages compared to conventional continuous wave (CW) approach, preventing laser induced thermal damage and related treatment side effects.

This study investigates the effect of sub-threshold (micropulse) laser treatment for dry eye disease due to meibomian gland dysfunction combined with increased eyelid margin vascularity.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-09-05
• Status Verified: 2020-06
• Study First Submitted: 2020-06-04
• Study First Submitted QC: 2020-06-06
• Last Update Submitted: 2020-06-06
• Study First Posted: 2020-06-11
• Last Update Posted: 2020-06-11
• Primary Completion: 2020-09
• Study Completion: 2021-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• 18-80 years
• chief complaint of more than one of dryness, foreign-body sensation, burning, and tearing for 3 months
• diagnosis of MGD with palpebral telangiectasia in both eyes

Exclusion Criteria

• ocular structural abnormalities
• history of ocular trauma or surgery
• use of any treatment for DE or MGD, other than artificial tears, within the past month
• active allergy, infection, or inflammatory disease at the ocular surface unrelated to DE or MGD
• lacrimal drainage-system anomalies
• contact-lens wear
• use of any systemic anti-inflammatory medicine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from Baseline Lower Eyelid Margin Vascularity	Baseline, Day 0 after treatment, Day 14 after treatment, Day 30 after treatment, Day 60 after treatment	Lower Eyelid Margin Vascularity is measured with ImageJ® software for vessels analysis from photographs of lower eyelid margin. Vascularity is evaluated as percentage (%) of lower eyelid margin surface. Time points are referred at ''Time Frame'' section.

Secondary Outcome Measures

Name	Time	Method
Ocular Surface Disease Index (OSDI)	Baseline, Day 14 after treatment, Day 30 after treatment, Day 60 after treatment	scale (0-100). Higher values represent greater disability.
Lower Eyelid Tear Meniscus Height	Baseline, Day 14 after treatment, Day 30 after treatment, Day 60 after treatment	height (μm)
Meibomography	Baseline, Day 14 after treatment, Day 30 after treatment, Day 60 after treatment	scale (0,1,2,3). Higher values represent greater disability.
Tear Break Up Time (TBUT)	Baseline, Day 14 after treatment, Day 30 after treatment, Day 60 after treatment	time (seconds). Higher values represent greater disability.

Trial Locations

Locations (1)

Naval Hospital of Athens; 🇬🇷 Athens, Greece